The Cancer LetterOvjeren akaunt

@TheCancerLetter

The leading source for information on the issues that shape oncology since 1973. Editor: Paul Goldberg | Associate editor: Matthew Ong

Washington, D.C.
Vrijeme pridruživanja: ožujak 2009.

Tweetovi

Blokirali ste korisnika/cu @TheCancerLetter

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TheCancerLetter

  1. .'s Thomas Lynch: "We need to make translational oncology a big part of what we do as we move forward, and I’ve tried to emphasize that at Yale, at Bristol-Myers, at MGH, and I’m going to make that a big part of what we do here at the Hutch." —

    Poništi
  2. . has launched 2 initiatives to increase minority representation in cancer clinical trials by amending its grant application requirements & funding a new research team focused on diversity and inclusion. — 

    Poništi
  3. Predictive Technology Group and Atrin Pharmaceuticals collaborate on molecular diagnostic oncology development

    Poništi
  4. proslijedio/la je Tweet
    3. velj

    Following up on last week’s , please help us make cancer clinical trials available to everyone, it will be a team effort but we’re pushing forward

    Poništi
  5. The U.S. released its first report in 30 years on smoking cessation. The report notes that “there is presently inadequate evidence to conclude that e-cigarettes, in general, increase smoking cessation.”

    Poništi
  6. In 2019, we lost oncology legend & pioneer, Dr. Bernard Fisher (, )—this issue looking back at the scandal that rocked his career is open access for

    Poništi
  7. The two Q&As from this story are open access, too. Jeff Allen (): & all ten "frenemy" health care research organizations:

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  8. for : Big steps taken in in 2019. : “The idea of collaboration, on a scale like this, with the speed to which these projects got done is pretty remarkable."

    Prikaži ovu nit
    Poništi
  9. The next story we're opening up for is a look into the most-discussed plenary session of : How a hackathon team linked expansion with reduction in racial disparities in time to cancer treatment —

    Poništi
  10. University of California San Diego School of Medicine researchers used genetically engineered human pluripotent stem cells to create a cancer model to study in vivo how glioblastoma develops and changes over time.

    Poništi
  11. U.S. Laureates William Kaelin () and Gregg Semenza () have a message for young scientists: do science for its own sake—and enjoy it.

    Poništi
  12. On , consider the impact of new drugs on mortality in this piece by (): "Rigorous research, visionary drug regulation, and relentless public health measures have brought about tangible change."

    Poništi
  13. In honor of , The Cancer Letter is making select stories with a broad impact open access, starting with a piece by : "Only one in four Americans (24%) incorporates cancer prevention into their daily lives." —

    Poništi
  14. .'s on project TEACH: "The goal is to have this army of black women who are informed about the clinical research process ... who can then help other women engage in that process to get the best possible outcomes." —

    Poništi
  15. . has updated its grant application requirements to increase diversity in cancer clinical trials. Read about the new requirements here:

    Poništi
  16. Eileen Smith was appointed chair of the Department of Hematology & Hematopoietic Cell Transplantation at .

    Poništi
  17. . established a new cancer center, The Mark Foundation Center for Advanced Genomics and Imaging. The center will initially receive $5 million over two years from the Mark Foundation .

    Poništi
  18. Thomas J. Lynch, new cancer center director at : "The bottom line is that we need new ideas that come from transformational basic science—much of which happens in the academic setting." Read our full Q and A here:

    Poništi
  19. Surgeon General’s report notes lack of evidence on in smoking cessation — 

    Poništi
  20. . initiatives aim to boost diversity in cancer trials — 

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·